4.0 Article

National Patterns in Antidepressant Medication Treatment

Journal

ARCHIVES OF GENERAL PSYCHIATRY
Volume 66, Issue 8, Pages 848-856

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/archgenpsychiatry.2009.81

Keywords

-

Categories

Funding

  1. National Institutes of Health (NIH)
  2. Agency for Healthcare Research and Quality
  3. American Foundation for Suicide Prevention
  4. National Association for Research on Schizophrenia and Affective Disorders
  5. New York State Office of Mental Health
  6. AstraZeneca, PLC
  7. Bristol-Myers Squibb Co
  8. Eli Lilly and Company
  9. Ortho-McNeil Janssen Scientific Affairs, LLC
  10. NIH
  11. National Patent Safety Foundation
  12. Bristol-Myers Squibb Co
  13. AstraZeneca, PLC
  14. Agency for Healthcare Research and Quality [U18-HS016097]
  15. National Alliance for Research on Schizophrenia and Depression

Ask authors/readers for more resources

Context: Antidepressants have recently become the most commonly prescribed class of medications in the United States. Objective: To compare sociodemographic and clinical patterns of antidepressant medication treatment in the United States between 1996 and 2005. Design: Analysis of antidepressant use data from the 1996 (n=18 993) and 2005 (n=28 445) Medical Expenditure Panel Surveys. Setting: Households in the United States. Participants: Respondents aged 6 years or older who reported receiving at least 1 antidepressant prescription during that calendar year. Main Outcome Measures: Rate of antidepressant use and adjusted rate ratios (ARRs) of year effect on rate of antidepressant use adjusted for age, sex, race/ethnicity, annual family income, self-perceived mental health, and insurance status. Results: The rate of antidepressant treatment increased from 5.84% (95% confidence interval [CI], 5.47-6.23) in 1996 to 10.12% (9.58-10.69) in 2005 (ARR, 1.68; 95% CI, 1.55-1.81), or from 13.3 to 27.0 million persons. Significant increases in antidepressant use were evident across all sociodemographic groups examined, except African Americans (ARR, 1.13; 95% CI, 0.89-1.44), who had comparatively low rates of use in both years (1996, 3.61%; 2005, 4.51%). Although antidepressant treatment increased for Hispanics (ARR, 1.75; 95% CI, 1.60-1.90), it remained comparatively low (1996, 3.72%; 2005, 5.21%). Among antidepressant users, the percentage of patients treated for depression did not significantly change (1996, 26.25% vs 2005, 26.85%; ARR, 0.95; 95% CI, 0.83-1.07), although the percentage of patients receiving antipsychotic medications (5.46% vs 8.86%; ARR, 1.77; 95% CI, 1.31-2.38) increased and those undergoing psychotherapy declined (31.50% vs 19.87%; ARR, 0.65; 95% CI, 0.56-0.72). Conclusions: From 1996 to 2005, there was a marked and broad expansion in antidepressant treatment in the United States, with persisting low rates of treatment among racial/ethnic minorities. During this period, individuals treated with antidepressants became more likely to also receive treatment with antipsychotic medications and less likely to undergo psychotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available